BMB-201 is a serotonin 5-HT2A and 5-HT2C receptor agonist of the tryptamine family described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications. Its route of administration is unspecified.
Pharmacology
BMB-201 is a prodrug of another compound known as BMB-A39a. This active metabolite acts as a biased partial agonist of the serotonin 5-HT2A and 5-HT2C receptors. BMB-A39a is slightly less efficacious in activating Gq signaling at the serotonin 5-HT2A and 5-HT2C receptors compared to psilocin (EmaxTooltip Maximal efficacy = 68% vs. 82% at 5-HT2A and 79% vs. 95% at 5-HT2C, respectively). It is about 9-fold less potent in activating the serotonin 5-HT2A receptor than psilocin, whereas its potency in activating the serotonin 5-HT2C receptor is similar to that of psilocin. Relatedly, whereas psilocin shows balanced activation of both the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is about 11-fold more potent in activating the serotonin 5-HT2C receptor over the serotonin 5-HT2A receptor. In addition to the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT1F and 5-HT6 receptors. On the other hand, it shows minimal or negligible activity in activating the serotonin 5-HT2B receptor (Emax < 20%), and does not activate other serotonin receptors, for instance the serotonin 5-HT1B and 5-HT1D receptors. BMB-A39a shows less than 70% efficacy in activating Gq signaling at the serotonin 5-HT2A receptor, which has been associated with absence of hallucinogenic-like activity. Accordingly, BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT2A receptor intrinsic activity but to potently induce neuroplasticity. It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.
Chemistry
The exact chemical structure of BMB-201 does not yet appear to have been disclosed. However, it is known to be a tryptamine derivative. In addition, Bright Mind Biosciences has patented tryptamines and prodrugs as serotonin 5-HT2 receptor modulators, including for example 7-methylpsilocin and 7-methylpsilocybin.
Research BMB-201 is under development by Bright Minds Biosciences. As of September 2025, it is in the preclinical research stage of development for the treatment of depressive disorders and pain.
See also List of investigational hallucinogens and entactogens Substituted tryptamine Non-hallucinogenic 5-HT2A receptor agonist BMB-101 BMB-105 BMB-202 Pharm-136
References
External links Pipeline - Bright Minds Biosciences 7-Methylpsilocin - Isomer Design